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Abstract
The effect of race on breast cancer outcome is confounded by tumor and treatment heterogeneity. 
We examined a cohort of women with stage II–III breast cancer treated uniformly with 
neoadjuvant chemotherapy to identify factors associated with racial differences in 
chemotherapeutic response and long-term survival. Using a prospective database, we identified 
women with stage II-III breast cancer treated with neoadjuvant chemotherapy from 1998 to 2011. 
Race was categorized as African-American (AA) or non-AA. Preplanned subtype analyses were 
stratified by hormone receptor (HR) and HER2. Pathologic response to chemotherapy (pCR), time 
to recurrence (TTR), and overall survival (OS) were assessed using logistic regression, Kaplan–
Meier method, and Cox proportional hazards regression analyses. Of 349 women identified, 102 
(29 %) were AA, who were younger (p = 0.03), more obese (p < 0.001), and less likely to have 
HR+/HER2–tumors (p = 0.01). No significant differences in pCR rate by race were found. At 
median follow-up of 6.5 years, AA had worse TTR (hazard ratio 1.51, 95 % CI 1.02–2.24), which 
was attenuated in multivariable modeling, and there was no significant difference in OS. When 
stratified by HR, worse outcomes were limited to HR+AA (TTR hazard ratio 1.85, 95 % CI 1.09–
3.14; OS hazard ratio 2.42 95 % CI 1.37–4.28), which remained significant in multivariable 
analysis including pCR rate and BMI. With long-term follow-up, racial disparity in outcome was 
limited to HR+ breast cancer, with no apparent contribution of chemotherapy sensitivity. This 
suggests that disparity root causes may be driven by HR+ factors such as unmeasured molecular 
differences, endocrine therapy sensitivity, or adherence.
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Introduction
Despite improvements in treatment and overall gains in breast cancer survival, racial 
disparities in breast cancer outcome are well documented and persistent over time [1–3], 
with age-adjusted mortality among AA women 40 % higher than Caucasian women (30.8 
vs. 22.1 deaths per 100,000) [4]. Disparities in outcome between AA and non-AA women 
are likely to be multifactorial with potential contributions from differences in breast cancer 
subtype frequencies, variability in comorbid conditions, access to and receipt of care, and 
other unmeasured biological factors. Advanced stage at diagnosis is more common for AA 
women but exhibit worse breast cancer-related outcomes even after stratification for stage 
compared to non-AA women [5, 6].Obesity is more prevalent in AA women compared to 
non-AA and is a prognostic variable for breast cancer survival, with poorly understood 
mechanisms to affect that endpoint [7–9]. Differences in access to care and treatment 
between race remain. Moreover some studies have found persistent racial disparities in 
outcome even among similarly treated women [10–12]. For example, a study from the U.S. 
Department of Defense, which entitles equal access to its health care system, demonstrated 
worse breast cancer survival rates among participating AA women than non-AA [13]. A 
case-control study of 317 AA and matched non-AA women participating in adjuvant 
cooperative group trials also found worse disease-free survival among AAs despite identical 
therapy [14].
Although AA women are more likely to have poor prognosis breast cancer subtypes [3, 15, 
16], the core of race disparity in breast cancer outcomes may lie in HR + subtypes. An 
analysis of outcome by race in the population-based Carolina Breast Cancer Study (CBCS) 
found that the greatest racial difference in survival was seen in the good prognosis HR+/
HER2 subset [17]. Similarly, in a randomized Phase III trial in which women were treated 
with adjuvant doxorubicin/cyclophosphamide (AC) chemotherapy and either paclitaxel (T) 
or docetaxel (Td), AA women with the HR+/HER2- subtype demonstrated worse disease-
free and overall survival compared to non-AA women of the same subtype, whereas no 
difference in outcome was seen in triple-negative or HER2+ disease [18]. Those studies 
could not identify whether treatment responsiveness contributed to this outcome differential.
The neoadjuvant setting offers a rich opportunity to examine chemotherapeutic response as 
well as long-term outcomes among patients treated in a uniform manner. A large cohort 
study including HR+ disease treated with neoadjuvant therapy did not find a difference in 
pCR by race but did find a trend toward worse long-term survival outcomes among AA 
women. That particular study was limited by very low pCR rates and short follow-up of only 
30 months making subtype-stratified survival analysis difficult [19]. In contrast, a study 
limited to triple-negative stage I–III breast cancers treated with neoadjuvant therapy found 
that race did not affect either response or survival in this subtype [20]. Taken together, these 
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studies suggest that racial disparities in AA breast cancer survival may be more driven by 
factors related to HR+ disease than HR–.
The current study seeks to further define racial differences in subtype-specific outcomes 
using a prospectively maintained database of neoadjuvantly treated breast cancer patients at 
the University of North Carolina. Detailed clinical information in this database includes 




The study population is derived from the prospectively annotated, IRB-approved 
Neoadjuvant Database at the University of North Carolina, Lineberger Comprehensive 
Cancer Center. Race was according to patient self-report as documented in the medical 
record. The database is updated every 6 months and includes serial clinical, radiographic, 
and pathologic tumor measurement, treatment details, toxicity, and outcome. The cohort 
eligible for analysis consisted of women with adenocarcinoma of the breast with or without 
axillary lymph node metastases treated with neoadjuvant chemotherapy. Included patients 
had clinical stage II–III breast cancer at presentation including inflammatory breast cancers 
and had no evidence of distant metastases according to the American Joint Commission on 
Cancer, Fifth Edition [21]. Each tumor in bilateral or multi-centric disease was measured 
separately. Inflamma-tory breast cancer was clinically defined based on erythema with an 
erysipeloid edge or peau d'orange changes with or without dermal lymphatic invasion.
Receptor status was based on clinical assays including immunohistochemical (IHC) markers 
for hormone receptor (HR) status. HER2 status was determined by IHC with fluorescence in 
situ hybridization (FISH) confirmation. IHC subtypes were categorized as HR +/HER2-; HR
+/ HER2+; HR-/HER2-; and HR-/HER2+. Pathologic complete response (pCR) was defined 
as the absence of residual invasive breast cancer in the breast or axillary lymph nodes; 
residual noninvasive disease was allowed [22]. Race was categorized as AA versus non-AA 
for all analyses.
Treatment
Neoadjuvant chemotherapy was categorized as (1) anthracycline-based (A) with no taxane, 
(2) taxane-based (T) with no anthracycline, or (3) both an anthracycline and a taxane (A+T). 
Completion of neoadjuvant A and/or T chemotherapy was defined as receipt of A ≥ 4 cycles 
and/ or T as ≥12 weekly cycles or T as ≥4 cycles every 2 or 3 weeks.
Medical records were reviewed to assess initiation and completion of endocrine or HER2-
targeted adjuvant therapy for appropriate HR+ or HER2+ tumors and for body mass index 
(BMI). Completion of adjuvant endocrine therapy was defined by documentation of 
tamoxifen and/or aromatase inhibitor (AI) use for at least 4.5 years; anti-HER2 therapy 
completion was defined as 1 year of adjuvant trastuzumab. Daily medication adherence was 
unable to be adequately assessed in this cohort, and therefore not measured. Incomplete 
endocrine therapy was defined as treatment duration less than 4.5 years. The definition of 
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incomplete endocrine therapy also included non-persistence of therapy longer than 6 months 
within 4.5 years of treatment. Women lost to follow-up prior to the defined period of 
endocrine therapy completion (4.5 years) were excluded from analysis (n = 18). Follow-up 
data abstraction was completed on August 31, 2012.
Statistical methods
Fisher's Exact and Wilcoxon rank sum tests were used to compare characteristics between 
AA and non-AA patients, in addition to evaluating associations with pCR. The Kaplan–
Meier method was used to estimate and compare TTR and OS, and hazard ratios were 
estimated using Cox regression models. Multivariable logistic and Cox regression models 
evaluated the combined effect of covariates on outcomes of pCR, TTR, and OS. Variables 
included in the modeling of probability of pCR and survival included subtype, body mass 
index (BMI), age, stage at diagnosis, and race. Models for TTR and OS also included pCR 
as a time-varying covariate. Limited multivariable modeling, due to small sample size, was 
done separately within the HR ± cohorts. TTR was defined as time from diagnosis to local 
recurrence or distant recurrence, whichever occurred first, and deaths without recurrence 
were censored. Those with no events were censored at last contact. OS was defined as time 
from diagnosis to death, with patients censored at last contact. Unadjusted two-sided p 




A total of 349 women with clinical stage II-III breast cancer were included, of whom 102 
(29 %) were AA (Table 1). Patients included in the non-AA demographic self-identified as 
Caucasian (224, 64 %), Hispanic (17, 5 %), Asian (1, <1 %), American Indian (1, <1 %), 
and “other” (4, 1 %). Consistent with previous studies, AA women were significantly 
younger, and obesity, defined as BMI ≤ 30 kg/m2, was more prevalent in AA women (62 vs. 
28 %, p < 0.001). In this high-risk cohort, 3 (<1 %) women had bilateral breast cancer, 85 
(24 %) had multi-centric or multi-focal disease, and the remaining were unifocal (76 %). 
Eighteen percent of patients had inflammatory disease, which was equally represented 
between AA (19 %) and non-AA (18 %) women. The representation of poorly differentiated 
tumors was similar between cohorts (grade 3 tumors at diagnosis: AA 69 % vs non-AA 65 
%, p = 0.5) (Table 1). The largest IHC subtype group was HR+/HER2- (42 %), followed by 
HR–/HER2–(30 %), HR+/HER2+ (15 %), and HR-/HER2+ (13 %). As expected, the 
distribution of subtypes differed significantly by race (p = 0.01), with a disproportionate 
percentage of AA women having HR-/HER2–, or triple-negative disease. Since 
progesterone receptor (PR) expression is seen as a prognostic differentiator in recurrence-
free survival, this cohort was assessed and no difference was observed between AA and non-
AA PR-tumors (p = 0.8) [23, 24].
Treatment received
Of the 349 women prescribed neoadjuvant chemotherapy, 291 (84 %) patients received 
combination of anthracycline/taxane-based treatment (Table 1). Of these women nearly half 
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(141, 48 %) received dose-dense every-2-weeks doxorubicin/cyclophosphamide for 4 cycles 
followed by paclitaxel either every 2 weeks for 4 cycles or 12 weekly cycles (ddAC-T). 30 
patients (9 %) received anthracycline-based therapy without a taxane, and 28 (8 %) received 
taxane-based therapy without an anthracycline. There was no significant difference in type 
of prescribed chemotherapy (anthracycline-based, taxane-based, or both) by race. No 
significant racial differences in completion of chemotherapy were observed, regardless of 
chemotherapy type (AA: 84/101, 83 %, vs. non-AA: 214/245, 87 %, p = 0.31). Forty-two 
patients (12 %) received additional chemotherapy postoperatively, without a difference in 
the receipt of adjuvant chemotherapy between AA and non-AA women (p = 1.0). No 
difference was seen in the receipt of radiation therapy, as treatment following either breast 
conservation surgery or mastectomy. Of those who received breast conservation treatment (n 
= 107), all but 1 received adjuvant radiation. Following mastectomy, almost all women (92 
%) received radiation and no significant difference was observed between AA (88 %) vs 
non-AA (94 %), p = 0.2 (Table 1).
Adjuvant endocrine therapy was received by most HR+ women (192/198, 97 %) with no 
significant difference seen in the prescription of endocrine therapy (tamoxifen and 
aromatase inhibitors) by race (p = 0.14) (Table 1). There were no significant differences in 
rates of endocrine therapy completion at 4.5 years, also known as treatment persistence, for 
women with HR + breast cancer (AA: 36/43, 84 %, vs. non-AA 118/144, 82 %, p = 0.49).
Trastuzumab was approved for adjuvant therapy of HER2+ breast cancer in 2005. Prior to 
that time, both neoadjuvant and adjuvant clinical trials of the agent were available. Receipt 
of trastuzumab in the neoadjuvant or adjuvant setting was less common for AA (15/26, 58 % 
AA, vs. 56/71, 79 % non-AA, p = 0.07).
Pathologic response to chemotherapy
Overall, 85 of 349 (24 %) patients achieved pCR to neoadjuvant chemotherapy (Table 1), 
with expected differences by clinical subtype (Supplemental Table 1). Although AA had 
uniformly lower rates of response (Supplemental Table 1), pCR rates did not significantly 
differ by race overall (21/102, 21 % AA vs 64/247, 26 % non-AA, p = 0.34) or when 
compared within any clinical subtype. A multivariable model including race, subtype, age, 
stage, and BMI did not find a significant difference in pCR rates for AAs compared to non-
AAs (OR 0.57, 95 % CI 0.31–1.06).
Recurrence and survival
There were 107 (31 %) breast cancer recurrences and 98 (28 %) deaths in this cohort. Most 
deaths during the study period were preceded by recurrence (81, 83 %), and of the women 
who recurred, 26 (24 %) were alive at time of last follow-up. Median follow-up of survivors 
was 6.5 years, and median OS for the entire cohort was 13.4 years. At 5 years, 73 % (95 % 
CI 68–77 %) were recurrence free and 79 % (95 % CI 74–83 %) were alive.
In univariable analyses, AAs had significantly higher risk of recurrence compared to non-
AA women (hazard ratio TTR: 1.51, 95 % CI 1.02–2.24, p = 0.04), although overall survival 
was not statistically significantly worse (hazard ratio OS: 1.47 95 % CI 0.98–4.28, p = 0.06). 
Tichy et al. Page 5













In multivariable models including subtype, stage, BMI, age, and pCR, race was not 
significantly associated with recurrence or death (Table 2); in the overall cohort, very strong 
and independent predictors of outcome were pCR and stage at diagnosis. No significant 
pairwise interactions of race, subtype, and BMI were identified. However, in stratified 
univariable analyses by HR status, significantly inferior outcomes for AA were identified, 
and were limited to the HR+ subset (Table 3). Five-year estimates for the percentage of 
patients who were recurrence free were 61 % (95 % CI 44–73 %) in AA and 78 % (95 % CI 
69–84 %) in non-AA women (p = 0.02) (Fig. 1a); similar discrepancies were seen for OS 
with five-year estimates of 65 % (95 % CI 49–78 %) in AA and 87 % (95 % CI 80–92 %) in 
non-AA (p = 0.002) (Fig. 1b). In multivariable models controlling for pCR and BMI, AA 
women in the HR+ subset had a significantly higher risk of recurrence and death when 
compared to non-AAs (hazard ratio TTR 1.91, 95 % CI 1.07–3.40 and OS 2.21, CI 95 % 
1.16–4.21) (Table 3). Sample size did not permit the analysis of fully adjusted models within 
the HR+ subset. Within the HR-cohort, differences in TTR and OS were significantly 
associated with pCR, but not with race (Table 3).
Discussion
This study found that AA breast cancer patients were younger, had higher BMI, and were 
more likely to have triple-negative breast cancer than their non-AA counterparts, all of 
which can contribute to racial disparities in outcome. However, the factors most strongly 
associated with survival were pathologic complete response to chemotherapy and stage at 
diagnosis, neither of which significantly differed between AA and non-AA (although it 
should be noted that this study was deliberately limited to stages II–III). A significant 
difference in outcome by race was seen in HR+ tumors, with a 20 % lower rate of survival at 
5 years for AA women, with no apparent difference among HR breast cancers. The AA and 
non-AA women in this cohort shared similar treatment patterns and rates of pathologic 
response with little evidence to suggest a difference in chemotherapeutic sensitivity.
This finding of racial disparity in outcomes driven by differences in HR+ subtypes mirrors 
and extends the findings of the population-based CBCS study, which found that the greatest 
racial disparity in outcome was noted in HR+ disease within a large cohort of patients with 
heterogeneous stages and treatments [17]. In an earlier study, Chavez-MacGregor and 
colleagues observed only a trend toward inferior outcomes in AA HR + patients treated with 
neoadjuvant therapy [19], but the median follow-up in that study was short and may have 
been immature for this clinical subset at risk for late relapses. Our findings contrast those 
presented from an Atlanta population-based study which demonstrated significantly worse 
survival for AA women with HR-tumors [25], but this study was limited to patients younger 
than 55 years of age, thus excluding a substantial subset of post-menopausal women.
The mainstay of systemic therapy for HR + breast cancer consists of at least 5 years of oral 
endocrine therapy. Our results as well as those of other investigators raise the question of 
whether racial differences in initiation, efficacy, or adherence to endocrine therapies may 
contribute to racial outcome disparities in this group. Both persistence (continuing to take 
the medication) and adherence (taking the medication at the prescribed dose and schedule) 
are known to be suboptimal among breast cancer patients. While literature on endocrine 
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therapy has generally indicated equivalent rates of persistence among AAs and whites [26–
30], several studies have found lower medication adherence among AA women [26, 27, 
29-32]; inadequate adherence is associated with worse outcomes [31]. We observed an 
equivalent rate of endocrine therapy persistence between AA and non-AA; however, this 
dataset was not able to address the specific question of endocrine therapy adherence.
With these findings, we must consider differences in estrogen metabolism and 
bioavailability as a possible explanation for the racial disparity in outcome. As the 
Suppression of Ovarian Function Trial (SOFT) suggested, improved breast cancer outcomes 
were seen in young women who received ovarian suppression and remained amenorrheic 
following chemotherapy [33]. It is plausible that a lower rate of chemotherapy-related 
amenorrhea in AA women, who are more likely to present pre-menopausal at diagnosis, may 
translate to worse long-term survival. Information related to menopausal status before and 
after breast cancer treatment was not obtained for this cohort, but warrants further 
consideration for future study. Lower sensitivity to endocrine therapy among AAs is also 
hypothesized. Lund and colleagues reported that AA women with HR+ tumors are more 
likely to present with higher 21-gene recurrence scores rendering endocrine therapy less 
effective for this group [34]. Obesity and its role in estrogen metabolism of breast tumors is 
complex and inconsistently associated with worse breast cancer outcome. The results of the 
ATAC trial suggested the benefit of aromatase inhibition was abrogated by higher body 
mass index [35]. AA women in our study were more likely to be obese (BMI ≥ 30 kg/m2), 
which may contribute to the worse outcome in this subset.
This study has several limitations. Although our sample contained a high proportion of AA 
women, the size of the cohort limits the detection of recurrence and survival differences by 
stratification, particularly among HER2+. While the cohort was assembled and outcome data 
collected prospectively, our analysis is retrospective. This limits our control over data 
elements not prospectively collected such as detailed information regarding adherence to 
endocrine therapy. We also do not have specific details regarding chemotherapy doses, 
timing of initiation, or treatment delays. However, institutional chemotherapy guidelines 
throughout the timeframe of this cohort recommended dosing according to actual weight 
rather than ideal weight, and therefore weight-based dose limits are unlikely to have affected 
the results. It should also be noted that clinical IHC-based subtypes were used and may not 
recapitulate tumor biology [36]; molecular subtype data for this cohort are not available.
In summary, among a cohort of women with stage II–III tumors treated similarly, we 
observed markedly worse long-term outcomes among AA patients with HR+ breast cancer. 
Within this subset, there appears to be an independent effect of race on breast cancer 
recurrence that is not explained by factors such as increased BMI or variations in persistence 
with prescribed endocrine therapy. The root causes of this racial disparity in outcome for 
AA women within those tumors considered least aggressive, and the most common, needs to 
be determined, including whether there are differences in endocrine therapy sensitivity, 
adherence, or other unmeasured biologic variables.
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Table 1
Patient characteristics and receipt of therapy
Overall Non-AA AA p value
Sample size 349 247 (70.7 %) 102 (29.2 %)
Age (median, range) 48 (24–78) 49 (24–78) 45 (27–69) 0.03
Tumor grade at diagnosis
    Grade III (65 %) (69 %) 0.50
Stage at diagnosis
    II 159 (45.6 %) 117 (47.3 %) 42 (41.2 %) 0.34
    III 190 (54.4 %) 130 (52.7 %) 60 (58.8 %)
Body mass index
    BMI (median, range) 27.6 (15.3, 70.7) 26.6 (15.4, 70.7) 31.6 (15.3, 60.9) <0.0001
    <30 216 (61.9 %) 177 (71.7 %) 39 (38.2 %) <0.0001
    ≥30 133 (38.1 %) 70 (28.3 %) 63 (61.8 %)
IHC subtype
    HR-/HER2– 105 (30.0 %) 61 (24.7 %) 44 (43.1 %) 0.01
    HR-/HER2+ 46 (13.2 %) 34 (13.8 %) 12 (11.7 %)
    HR+/HER2– 147 (42.1 %) 115 (46.5 %) 32 (31.4 %)
    HR+/HER2+ 51 (14.6 %) 37 (15.0 %) 14 (14.7 %)
Neoadjuvant regimen
    A + T 291 (83.5 %) 205 (83.0 %) 86 (84.3 %) 0.94
    A, no T 30 (8.5 %) 21 (8.5 %) 9 (8.8 %)
    T, no A 28 (8.0 %) 21 (8.5 %) 7 (6.9 %)
Adjuvant therapy
    Endocrine therapy receipt (HR+ only) 192/198 (97.0 %) 149/152 (98.0 %) 43/46 (93.4 %) 0.14
    Post-mastectomy radiation 184 (52.7 %) (94 %) (88 %) 0.20
Pathologic complete response (pCR)
    pCR event rate 85/349 (24.3 %) 64/247 (25.9 %) 21/102 (20.5 %) 0.34
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Table 2
Cox proportional hazard models of recurrence and overall survival (n = 349)
Time to recurrence hazard ratio (95 % CI) Overall survival hazard ratio (95 % CI)
Univariable Multivariable Univariable Multivariable
Race
    AA
1.51 (1.02–2.24)
* 1.29 (0.83–2.00) 1.47 (0.98–2.21) 1.17 (0.74–1.85)
    non-AA 1.00 1.00 1.00 1.00
Subtype
    HR–/HER2+ 0.83 (0.44–1.57) 0.99 (0.51–1.93) 0.93 (0.47–1.83) 1.16 (0.57–2.35)
    HR–/HER2– 0.99 (0.63–1.56) 1.18 (0.73–1.89) 1.48 (0.92–2.37)
1.91 (1.16–3.14)
*
    HR+/HER2+ 1.06 (0.60–1.87) 1.21 (0.68–2.14) 1.56 (0.88–2.75)
1.89 (1.07–3.37)
*
    HR+/HER2– 1.00 1.00 1.00 1.00
Stage









    II 1.00 1.00 1.00 1.00
Body mass index (BMI) continuous 1.02 (1.00–1.04) 1.01 (0.98–1.01)
1.03 (1.01–1.05)
** 1.02 (0.99–1.04)
Age continuous 0.99 (0.97–1.01) 0.99 (0.97–1.01) 1.01 (0.99–1.03) 1.01 (0.99–1.03)
pCR
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Table 3
Adjusted cox proportional hazard models of recurrence and survival stratified by HR subset (n = 349)
Time to recurrence hazard ratio (95 % CI) Overall survival hazard ratio (95 % CI)
Univariable Multivariable Univariable Multivariable
HR–
        AA vs non-AA 1.40 (0.77–2.55) 1.07 (0.58–1.98) 1.00 (0.55–1.82) 0.76 (0.41–1.41)
    pCR









            No
        BMI 1.03 (1.00–1.07) 1.03 (0.99–1.07) 1.02 (0.99–1.06) 1.02 (0.99–1.05)
HR+









    pCR
            Yes 0.32 (0.10–1.03)
0.31 (0.10–1.00)
* 0.27 (0.07–1.10) 0.26 (0.06–1.08)
            No
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